Table 2.
PFS | OS | |||||
---|---|---|---|---|---|---|
HR | 95% CI | P‐value | HR | 95% CI | P‐value | |
Age, <60 vs ≧60 | 1.3 | 0.6–2.9 | 0.46 | 1.4 | 0.5–3.9 | 0.54 |
Gender, M vs F | 1.2 | 0.6–2.6 | 0.56 | 2.4 | 0.8–10.5 | 0.25 |
Stage, T1 vs T2 + 3+4 | 3.4 | 1.6–7.5 | <0.001 | 2.8 | 1.1–8.2 | 0.037 |
Nuclear grade, G1 + 2 vs G3 + 4 | 5.2 | 2.4–11.1 | <0.001 | 5.3 | 1.8–14.9 | 0.003 |
CD44, negative vs positive | 1.9 | 0.8–4.2 | 0.14 | 1.3 | 0.4–3.6 | 0.68 |
CI, confidential interval; HR, hazard ratio; OS, overall survival; PFS, progression free survival.